Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Liabilities: 2010-2025

Historic Total Liabilities for Altimmune (ALT) over the last 15 years, with Sep 2025 value amounting to $32.8 million.

  • Altimmune's Total Liabilities rose 126.73% to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 126.73%. This contributed to the annual value of $15.8 million for FY2024, which is 4.49% down from last year.
  • Altimmune's Total Liabilities amounted to $32.8 million in Q3 2025, which was up 13.33% from $29.0 million recorded in Q2 2025.
  • Altimmune's 5-year Total Liabilities high stood at $32.8 million for Q3 2025, and its period low was $14.5 million during Q3 2024.
  • Its 3-year average for Total Liabilities is $19.2 million, with a median of $16.2 million in 2023.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 30.58% in 2021, then spiked by 126.73% in 2025.
  • Quarterly analysis of 5 years shows Altimmune's Total Liabilities stood at $19.7 million in 2021, then increased by 9.66% to $21.6 million in 2022, then decreased by 23.55% to $16.5 million in 2023, then declined by 4.49% to $15.8 million in 2024, then soared by 126.73% to $32.8 million in 2025.
  • Its last three reported values are $32.8 million in Q3 2025, $29.0 million for Q2 2025, and $15.1 million during Q1 2025.